| 商标名 | 通用名称 | 中文名称 | ATC编码 | 授权日期 | 上市许可持有人 | 市场状态 |
|---|---|---|---|---|---|---|
| Nexviadyme | Avalglucosidase alfa | 艾夫糖苷酶α | A16 | 2022-06-24 | Sanofi B.V. | Authorised |
| Cabometyx | cabozantinib | L01EX07 | 2016-09-09 | Ipsen Pharma | Authorised | |
| Cometriq | cabozantinib | 苹果酸卡博替尼 | L01XE | 2014-03-21 | Ipsen Pharma | Authorised |
| Bimervax | COVID-19 Vaccine (recombinant, adjuvanted);selvacovatein | J07BN | 2023-03-30 | Hipra Human Health S.L. | Authorised | |
| Upstaza | eladocagene exuparvovec | 艾依卡基 | A16AB26 | 2022-07-18 | PTC Therapeutics International Limited | Authorised |
| Vitrakvi | larotrectinib | 硫酸拉罗替尼 | L01XE53 | 2019-09-19 | Bayer AG | Authorised |
| Elonva | corifollitropin alfa | 绒促卵泡素α | G03GA09 | 2010-01-25 | N.V. Organon | Authorised |
| Caelyx pegylated liposomal | doxorubicin | 盐酸多柔比星 | L01DB | 1996-06-20 | Baxter Holding B.V. | Authorised |
| RotaTeq | rotavirus vaccine, live | 轮状病毒减毒活疫苗 | J07BH02 | 2006-06-26 | Merck Sharp & Dohme B.V. | Authorised |
| Dapagliflozin Viatris | dapagliflozin | 达格列净 | A10BK01 | 2023-03-24 | Viatris Limited | Authorised |
| Orgalutran | ganirelix | 醋酸加尼瑞克 | H01CC01 | 2000-05-16 | N.V. Organon | Authorised |
| Briviact (in Italy: Nubriveo) | brivaracetam | 布瓦西坦 | N03AX23 | 2016-01-13 | UCB Pharma SA | Authorised |
| RoActemra | tocilizumab | 托珠单抗 | L04AC07 | 2009-01-16 | Roche Registration GmbH | Authorised |
| Fuzeon | enfuvirtide | 恩夫韦肽 | J05AX07 | 2003-05-27 | Roche Registration GmbH | Authorised |
| COVID-19 Vaccine (inactivated, adjuvanted) Valneva | COVID-19 vaccine (inactivated, adjuvanted, adsorbed) | J07BX03 | 2022-06-24 | Valneva Austria GmbH | Withdrawn | |
| Thyrogen | thyrotropin alfa | 促甲状腺素α | H01AB01 | 2000-03-09 | Sanofi B.V. | Authorised |
| Skyrizi | risankizumab | 利生奇珠单抗 | L04AC18 | 2019-04-26 | AbbVie Deutschland GmbH & Co. KG | Authorised |
| Hepcludex | bulevirtide | 布乐韦肽 | J05A | 2020-07-31 | Gilead Sciences Ireland UC | Authorised |
| Myozyme | alglucosidase alfa | 阿糖苷酶α | A16AB07 | 2006-03-28 | Sanofi B.V. | Authorised |
| Tremelimumab AstraZeneca | tremelimumab | 曲美木单抗 | L01FX20 | 2023-02-20 | AstraZeneca AB | Withdrawn |
